The patient experience of pulmonary hypertension: a large cross-sectional study of UK patients.


Journal

BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563

Informations de publication

Date de publication:
21 Mar 2019
Historique:
received: 21 08 2018
accepted: 03 03 2019
entrez: 23 3 2019
pubmed: 23 3 2019
medline: 9 8 2019
Statut: epublish

Résumé

Pulmonary Hypertension Association UK (PHA-UK) is the only charity in the UK especially for people affected by pulmonary hypertension (PH). To better understand the impact of PH on patients and carers beyond clinical symptoms, the PHA-UK carried out a cross-sectional survey on the effect of PH on daily living, along with a follow-up survey assessing the financial impact of PH. This is a descriptive cross-sectional survey of adult patients with PH in the UK. A quantitative survey of four key topics (time to diagnosis, quality of life [QoL], financial impact and specialist treatment), was made available to PHA-UK members and patients on PH therapy, with a follow-up financial impact survey sent to those responders who agreed to be contacted further. Data collection was carried out in January and February 2017 for the main survey, and November and December 2017 for the financial impact survey. The main survey was completed by 567 individuals, and the financial follow-up survey by 171. Mean age of responders was 69 ± 17 years with 70% female. 60% of respondents said PH had a major impact on their QoL, with 45% reporting that treatment and management improves their QoL 'a lot'. The time between first experiencing symptoms and diagnosis was ≥1 year for 48% of patients, with 40% seeing 4+ doctors before diagnosis. 63% of patients reported financial worries. Patients in part-time and full-time work reported the greatest financial burden, with a 13 and 33% fall in monthly income respectively. Patients had positive experiences of treatment in specialist centres, with 62% rating their care 'excellent', and 92% saying they preferred travelling to a specialist centre rather than seeing a local non-specialist. This study reports the largest UK survey exploring issues affecting patients with PH. The study shows that despite the availability of new therapies, patients are still experiencing delays prior to diagnosis, and experiencing both emotional and financial impacts from the disease. By identifying the areas patients find most important in their treatment, this research can inform future care policies and long-term management to support patients living with PH and their families.

Sections du résumé

BACKGROUND BACKGROUND
Pulmonary Hypertension Association UK (PHA-UK) is the only charity in the UK especially for people affected by pulmonary hypertension (PH). To better understand the impact of PH on patients and carers beyond clinical symptoms, the PHA-UK carried out a cross-sectional survey on the effect of PH on daily living, along with a follow-up survey assessing the financial impact of PH.
METHODS METHODS
This is a descriptive cross-sectional survey of adult patients with PH in the UK. A quantitative survey of four key topics (time to diagnosis, quality of life [QoL], financial impact and specialist treatment), was made available to PHA-UK members and patients on PH therapy, with a follow-up financial impact survey sent to those responders who agreed to be contacted further. Data collection was carried out in January and February 2017 for the main survey, and November and December 2017 for the financial impact survey.
RESULTS RESULTS
The main survey was completed by 567 individuals, and the financial follow-up survey by 171. Mean age of responders was 69 ± 17 years with 70% female. 60% of respondents said PH had a major impact on their QoL, with 45% reporting that treatment and management improves their QoL 'a lot'. The time between first experiencing symptoms and diagnosis was ≥1 year for 48% of patients, with 40% seeing 4+ doctors before diagnosis. 63% of patients reported financial worries. Patients in part-time and full-time work reported the greatest financial burden, with a 13 and 33% fall in monthly income respectively. Patients had positive experiences of treatment in specialist centres, with 62% rating their care 'excellent', and 92% saying they preferred travelling to a specialist centre rather than seeing a local non-specialist.
CONCLUSIONS CONCLUSIONS
This study reports the largest UK survey exploring issues affecting patients with PH. The study shows that despite the availability of new therapies, patients are still experiencing delays prior to diagnosis, and experiencing both emotional and financial impacts from the disease. By identifying the areas patients find most important in their treatment, this research can inform future care policies and long-term management to support patients living with PH and their families.

Identifiants

pubmed: 30898139
doi: 10.1186/s12890-019-0827-5
pii: 10.1186/s12890-019-0827-5
pmc: PMC6429756
doi:

Types de publication

Journal Article

Langues

eng

Pagination

67

Références

Psychosom Med. 2004 Nov-Dec;66(6):831-6
pubmed: 15564346
Am J Respir Crit Care Med. 2006 May 1;173(9):1023-30
pubmed: 16456139
Chest. 2010 Feb;137(2):376-87
pubmed: 19837821
Psychosomatics. 2010 Jul-Aug;51(4):339-339.e8
pubmed: 20587763
Chest. 2011 Jul;140(1):19-26
pubmed: 21393391
Eur Respir J. 2012 Apr;39(4):945-55
pubmed: 21885399
Pulm Circ. 2013 Jan;3(1):89-94
pubmed: 23662179
Eur Respir Rev. 2013 Dec;22(130):535-42
pubmed: 24293469
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D42-50
pubmed: 24355641
Nurs Health Sci. 2014 Dec;16(4):454-60
pubmed: 24730424
Lancet Respir Med. 2016 Apr;4(4):306-22
pubmed: 26975810
J Heart Lung Transplant. 2017 Sep;36(9):957-967
pubmed: 28302503
Medicine (Baltimore). 2017 Sep;96(39):e6783
pubmed: 28953608

Auteurs

Iain Armstrong (I)

Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, S10 2JF, UK. iain@phauk.org.
Pulmonary Hypertension Association UK (PHA-UK), Chapeltown, Sheffield, UK. iain@phauk.org.

Catherine Billings (C)

Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, S10 2JF, UK.
Pulmonary Hypertension Association UK (PHA-UK), Chapeltown, Sheffield, UK.

David G Kiely (DG)

Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, S10 2JF, UK.
Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.

Janelle Yorke (J)

School of Health Sciences, University of Manchester, Oxford Road, Manchester, M139PL, UK.

Carl Harries (C)

Pulmonary Hypertension Unit, Royal Brompton and Harefield NHS Foundation Trust, London, UK.

Shaun Clayton (S)

Pulmonary Hypertension Association UK (PHA-UK), Chapeltown, Sheffield, UK.

Wendy Gin-Sing (W)

Pulmonary Hypertension CNS, Hammersmith Hospital, Du Cane Road, London, W12 0HS, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH